Legacy Private Trust Co. Makes New $216,000 Investment in The Clorox Company (NYSE:CLX)

Legacy Private Trust Co. bought a new position in shares of The Clorox Company (NYSE:CLX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 1,357 shares of the company’s stock, valued at approximately $216,000.

Several other institutional investors have also recently made changes to their positions in the company. American Century Companies Inc. lifted its position in Clorox by 18.0% during the 1st quarter. American Century Companies Inc. now owns 8,320 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,269 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Clorox by 6.8% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,465 shares of the company’s stock valued at $2,289,000 after purchasing an additional 1,044 shares during the last quarter. Cibc World Market Inc. boosted its position in shares of Clorox by 276.6% in the 1st quarter. Cibc World Market Inc. now owns 9,318 shares of the company’s stock worth $1,295,000 after purchasing an additional 6,844 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Clorox by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 683,818 shares of the company’s stock worth $95,073,000 after buying an additional 5,145 shares during the last quarter. Finally, Blair William & Co. IL increased its position in Clorox by 81.1% during the 1st quarter. Blair William & Co. IL now owns 24,525 shares of the company’s stock valued at $3,410,000 after buying an additional 10,981 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Clorox Stock Performance

CLX stock opened at $146.20 on Friday. The company has a debt-to-equity ratio of 6.38, a current ratio of 0.95 and a quick ratio of 0.59. The Clorox Company has a 1 year low of $124.58 and a 1 year high of $178.21. The company has a market cap of $18.10 billion, a P/E ratio of 122.86, a price-to-earnings-growth ratio of 2.13 and a beta of 0.28. The stock’s fifty day moving average price is $155.33 and its 200-day moving average price is $157.95.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, August 2nd. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.48. Clorox had a return on equity of 163.56% and a net margin of 2.02%. The company had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the prior year, the company earned $0.93 earnings per share. Clorox’s revenue was up 12.1% on a year-over-year basis. On average, equities analysts forecast that The Clorox Company will post 5.87 earnings per share for the current year.

Clorox Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 25th. Shareholders of record on Wednesday, August 9th were given a $1.20 dividend. The ex-dividend date of this dividend was Tuesday, August 8th. This is an increase from Clorox’s previous quarterly dividend of $1.18. This represents a $4.80 annualized dividend and a yield of 3.28%. Clorox’s dividend payout ratio (DPR) is presently 403.36%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CLX shares. Atlantic Securities raised Clorox from an “underweight” rating to a “neutral” rating in a research note on Thursday, August 3rd. StockNews.com raised shares of Clorox from a “hold” rating to a “buy” rating in a report on Friday, September 8th. DA Davidson increased their price target on shares of Clorox from $155.00 to $176.00 and gave the company a “neutral” rating in a report on Monday, August 7th. Finally, Barclays boosted their price objective on shares of Clorox from $117.00 to $127.00 and gave the stock an “underweight” rating in a report on Friday, August 4th. Six research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $150.38.

Insider Transactions at Clorox

In other news, CFO Kevin B. Jacobsen sold 3,346 shares of the company’s stock in a transaction on Monday, August 14th. The stock was sold at an average price of $160.82, for a total value of $538,103.72. Following the completion of the sale, the chief financial officer now directly owns 23,224 shares in the company, valued at approximately $3,734,883.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.41% of the company’s stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.